Deutsche Bank Research maintained a 'Buy' rating on Novartis AG with a price target of 140 Swiss francs, citing emerging optimism from two recent research notes regarding the HORIZON study of Pelacarsen, a lipid-lowering drug.
Emmanuel Papadakis, the analyst covering the stock, highlighted that the latest reports suggested potential positive outcomes from the trial, which is expected to influence investor sentiment. The Horizon study’s original data is scheduled for release on August 28, 2026, at 07:50 CET, according to the note.
Novartis shares, listed under ISIN CH0012005267, closed at 119.80 francs on Friday, implying a 17% gain to reach the bank’s target. The analyst did not provide additional details on the trial’s methodology or the specific findings referenced in the reports.
The rating and target remain unchanged from Deutsche Bank’s prior assessment, reflecting confidence in the drug’s potential despite the pending study results.
